Tromso, Norway

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.50M | Year: 2010

The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1). Viscogel has excellent adjuvant properties: strongly immunostimulatory, stable, easy to manufacture, pronounced depot effect and possibility to obtain products of GMP quality. In addition Viscogel is mucoadhesive and in combination with LTX cell penetrating, making it suitable for mucosal administration. The target applications to be demonstrated in the ViVac project are i) prophylactic vaccination against common infectious diseases, and ii) therapeutic allergy vaccination. Both application areas represent billion markets. Five RTD consortium partners with specific key competences will perform research to support further technical development and new IP opportunities for the participating SME partners. The research objectives are i) to provide pre-clinical and clinical proof-of-concept for prophylactic vaccination with a model vaccine against Hib (Haemophilus influenzae type b). Data supporting that Viscogel induces improved immune responses at lower vaccine doses will likely be applicable to most prophylactic vaccines. ii) to provide pre-clinical proof-of-concept for therapeutic vaccination, demonstrated for allergy vaccination. In particular Viscogel-Bet v 1 formulations for administration over the sublingual mucosa will be developed and thus fulfil an unmet medical need for safe, efficient and convenient allergy vaccination. A successful outcome of the ViVac project will significantly improve the competitive situation for the SME partners and create new commercialisation opportunities.


News Article | November 1, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Infectious Disease Treatment Market in China 2016-2020” new report to its research database. The report spread across 125 pages with table and figures in it. The Research analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020. Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/infectious-disease-treatment-market-in-china-2016-2020/ Covered in this report The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period. The Research report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors - F. Hoffmann-La Roche - Gilead Sciences - GSK - Johnson & Johnson - Merck - Pfizer Other prominent vendors - Achaogen - Actelion - Adenovir Pharma - AstraZeneca - Bayer - Biocryst - Celsus therapeutics - Cempra - Eleven Biotherapeutics - Exoxemis - Ferrer International - Griffin Discoveries - Hexima - InSite Vision - Insmed Incorporated - KaloBios Pharmaceuticals - Lytix Biopharma - Meiji Seika Pharma - Melinta Therapeutics - Moberg Pharma - NanoViricides - Nektar - NicOx - NovaBay - NovaBiotics - Ocular Therapeutix - Panoptes Pharma - Paratek Pharmaceuticals - Polichem - PTC Therapeutics - RedHill - Shire - Starpharma Holdings - Sun Pharma - Symbiomix - Tetraphase Pharmaceuticals - The Medicines Company - Theravance Biopharma - Topica Pharmaceuticals - Vertex Pharmaceuticals - Viamet Pharmaceuticals Market driver - Use of combination therapies - For a full, detailed list, view our report Market challenge - Development of drug resistant strains - For a full, detailed list, view our report Market trend - Emergence of interferon (IFN)-free therapies - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | November 29, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Diabetic Foot Ulcers - Pipeline Review, H2 2016 addition with 51 market data tables and 15 figures, spread across 157 page is available at http://www.reportsnreports.com/reports/764559-diabetic-foot-ulcers-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis ANP Technologies Inc,CardioVascular BioTherapeutics Inc,Celgene Corp,Chrysalis BioTherapeutics Inc,CytoTools AG,EyeGene Inc,FirstString Research Inc,Genentech Inc,GlaxoSmithKline Plc,Human Stem Cells Institute,Izun Pharmaceuticals Corp,Karyopharm Therapeutics Inc,Lakewood-Amedex Inc,Lytix Biopharma AS,Mallinckrodt Plc,MediWound Ltd,NovaLead Pharma Pvt Ltd,Oneness Biotech Co Ltd,Osiris Therapeutics Inc,Pherecydes Pharma SA,Plurogen Therapeutics Inc,TechnoPhage SA,TGV-Laboratories,Theravasc Inc,Topadur Pharma AG,USV Pvt Ltd,viDA Therapeutics Inc,ViroMed Co Ltd] Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764559premium report price at US$2000 for a single user PDF license).


Patent
Lytix Biopharma | Date: 2012-08-14

The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.


Patent
Lytix Biopharma | Date: 2010-11-02

The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted amino acid, each of the substituting groups in the amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.


Patent
Lytix Biopharma | Date: 2011-06-29

The invention relates to a peptide consisting of 2-4 amino acids comprising at least three lipophilic groups of at least 5 non-hydrogen atoms wherein one of the molecules lipophilic groups incorporates 6 or more non-hydrogen atoms and a second lipophilic group incorporates 10 or more non-hydrogen atoms and wherein at least one lipophilic group incorporates a closed ring of at least 6 non-hydrogen atoms, said peptide having at least one more cationic than anionic moiety, and wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the lipophilic groups is an amino acid side chain (R group), for use as an antitumoural agent and to a peptide consisting of 2-4 amino acids comprising a lipophilic group comprising at least 13 non-hydrogen atoms and one or more closed rings of 4 or more non-hydrogen atoms, wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the amino acid side chains (R groups) is a lipophilic group of at least 4 non-hydrogen atoms, said peptide having at least two more cationic than anionic moieties, also for use as an antitumoural agent.


Patent
Lytix Biopharma | Date: 2011-09-22

The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.


Patent
Lytix Biopharma | Date: 2015-02-04

The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R but may not be a quaternary C atom; R is OR_(1), CONH_(2), CF_(3), F, OH, NO_(2), CN or OCOR_(1 )in which R_(1), is C_(1-3 )alkyl and each may be in the beta or gamma position; R is C_(1-3 )alkyl or H; and R is H or a group consisting of 1-12 non-hydrogen atoms and may be linear, branched and/or incorporate one or more cyclic groups, cyclic groups may be aromatic and/or heterocyclic and 2 or more cyclic groups may be linked or fused and each may be substituted; or a salt, hydrate or solvate of a compound of formula (I) for use in the treatment or prevention of a neurodegenerative disorder by inhibiting formation of neurofibrillary (tau) tangles and/or by inhibiting Dyrk 1A. The invention further relates to non-therapeutic uses of these compounds.


Patent
Lytix Biopharma | Date: 2015-12-14

The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.


Patent
Lytix Biopharma | Date: 2012-01-04

The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.

Loading Lytix Biopharma collaborators
Loading Lytix Biopharma collaborators